Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Oxford Biomedica (Us) LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 2 examiners and 2 art units, so the portfolio is distributed across separate examination assignments. BLUMEL, BENJAMIN P is the busiest examiner, with 1 pending matter.
The available profile points to a small but divided prosecution workload. Counsel may need to track separate examiner positions and art-unit procedures rather than rely on a single response strategy. The busiest-examiner figure does not identify a dominant concentration, because only 1 matter is assigned to that examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 1631 | §102§103 | Non-Final OA | 69d | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOxford Biomedica (Us) LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Benjamin P Blumel has the most, with 1 of Oxford Biomedica (Us) LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
